Circulating tumour DNA tests for T790M mutations in non-small cell lung cancer
Topic Status Incomplete
The presence or absence of epidermal growth factor receptor (EGFR) T790M mutations in non-small cell lung cancer indicate which treatments are most likely to be effective. Biopsy of the tumour can be associated with morbidity such as pneumothorax, bleeding and infection. A less invasive alternative to tissue biopsy is to test a blood sample for EGFR T790M mutations in circulating tumour DNA.
Health Technology Wales researchers searched for clinical and cost effectiveness evidence on circulating tumour DNA tests for T790M mutations in people with advanced or metastatic non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Topic Exploration Report